OKYO Company Profile and Key Details

OKYO Pharma Limited has 37.61 million shares outstanding. The public float is 25.08 million shares, elevated short interest at 0.28% of float. This equals 77.25 thousand shares. The short ratio is 0.56 days. Institutional investors hold 11.05% of the float. Insiders own 33.31%. CERRONE GABRIELE M holds 62.50 thousand shares, BRANCACCIO JOHN P has 16.67 thousand shares and JACOB GARY S has 12.50 thousand shares.

Short-term trend indicators are mixed aligned (SMA20 4.0%, SMA50 -7.85%, SMA200 -2.45%). The stock’s 14-day RSI is 49.72 (neutral), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -39.38% below its high and over 125.16% above its low. Average 10-day trading volume of 91.52 thousand shares is below the 3-month average of 154.29 thousand, indicating normal recent market interest.

OKYO Pharma Limited generated EPS of -$0.14 over the past year. Five-year average earnings growth is -114.91%. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.05. Next year's EPS is expected at $0.00. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $5.00. The high target offers 244.83% upside. The low target suggests 146.31% downside. The mean target is $6.60. This offers 225.12% upside. OKYO Pharma Limited earnings surprise history is a mixed track record. The quarter that ended July 18, 2025, missed forecasts by 45.56%.

OKYO Pharma Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.04. This means the shares are trading above this model’s fair value.

OKYO Pharma Limited (NASDAQ:OKYO) closed at $2.03 USD, gaining $0.16 (8.56%) from the previous close of $1.87. The stock is currently mid-range between its 52-week high and low $0.90 and $3.35. With a market capitalization of about $76.35 million, OKYO Pharma Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.16). Key stats such as the average daily volume over the past year has been around 153.20 thousand shares, volume is running light vs its 52-week average. Headquartered in London, None, OKYO Pharma Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gary S. Jacob, the company employs approximately 3 people and listed since May 17, 2022. OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.

OKYO Pharma Limited trades at a P/E ratio of -17.03, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -14.44 indicating negative book value, which may reflect financial stress. The P/FCF stands at -42.11, also below market averages.

OKYO Pharma Limited (NASDAQ:OKYO) shares are up 76.52% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows OKYO Pharma Limited trading at a premium to the broader market with a P/E of -17.03. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.78, suggesting 233.99% upside. Our AI forecast model points to short-term weakness (-3.94% over two weeks), a medium-term fall (-11.82% over three months), and a longer-term gain (665.52% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that OKYO Pharma Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.94%, with price expected at $1.95 by January 02, 2026, within a range of $1.80 to $2.11 3-Month Outlook: Projected fall of -11.82%, reaching $1.79 by March 19, 2026, with a range of $1.52 to $1.93. 1-Year Outlook: Projected gain of 665.52%, with price at $15.54 by December 18, 2026, within a range of $16.06 to $18.80.